266 related articles for article (PubMed ID: 21718557)
1. ADHD in children and adolescents.
Keen D; Hadijikoumi I
BMJ Clin Evid; 2011 Feb; 2011():. PubMed ID: 21718557
[TBL] [Abstract][Full Text] [Related]
2. ADHD in children and adolescents.
Keen D; Hadijikoumi I
BMJ Clin Evid; 2008 Oct; 2008():. PubMed ID: 19445793
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders.
Osland ST; Steeves TD; Pringsheim T
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD007990. PubMed ID: 29944175
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis.
Cortese S; Adamo N; Mohr-Jensen C; Hayes AJ; Bhatti S; Carucci S; Del Giovane C; Atkinson LZ; Banaschewski T; Simonoff E; Zuddas A; Barbui C; Purgato M; Steinhausen HC; Shokraneh F; Xia J; Cipriani A; Coghill D;
BMJ Open; 2017 Jan; 7(1):e013967. PubMed ID: 28073796
[TBL] [Abstract][Full Text] [Related]
5. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials.
Catalá-López F; Hutton B; Núñez-Beltrán A; Page MJ; Ridao M; Macías Saint-Gerons D; Catalá MA; Tabarés-Seisdedos R; Moher D
PLoS One; 2017; 12(7):e0180355. PubMed ID: 28700715
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder.
Kaplan S; Heiligenstein J; West S; Busner J; Harder D; Dittmann R; Casat C; Wernicke JF
J Atten Disord; 2004 Oct; 8(2):45-52. PubMed ID: 15801334
[TBL] [Abstract][Full Text] [Related]
7. Depression in children and adolescents.
Hazell P
BMJ Clin Evid; 2011 Oct; 2011():. PubMed ID: 22018419
[TBL] [Abstract][Full Text] [Related]
8. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.
May DE; Kratochvil CJ
Drugs; 2010; 70(1):15-40. PubMed ID: 20030423
[TBL] [Abstract][Full Text] [Related]
9. Depression in children and adolescents.
Hazell P
BMJ Clin Evid; 2009 Jan; 2009():. PubMed ID: 19445770
[TBL] [Abstract][Full Text] [Related]
10. Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents.
Otasowie J; Castells X; Ehimare UP; Smith CH
Cochrane Database Syst Rev; 2014 Sep; (9):CD006997. PubMed ID: 25238582
[TBL] [Abstract][Full Text] [Related]
11. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).
Storebø OJ; Ramstad E; Krogh HB; Nilausen TD; Skoog M; Holmskov M; Rosendal S; Groth C; Magnusson FL; Moreira-Maia CR; Gillies D; Buch Rasmussen K; Gauci D; Zwi M; Kirubakaran R; Forsbøl B; Simonsen E; Gluud C
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD009885. PubMed ID: 26599576
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review.
Chan E; Fogler JM; Hammerness PG
JAMA; 2016 May; 315(18):1997-2008. PubMed ID: 27163988
[TBL] [Abstract][Full Text] [Related]
13. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
Garnock-Jones KP; Keating GM
Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
[TBL] [Abstract][Full Text] [Related]
14. Menopausal symptoms.
Morris EP; Burbos N
BMJ Clin Evid; 2010 Feb; 2010():. PubMed ID: 21718582
[TBL] [Abstract][Full Text] [Related]
15. [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].
Purper-Ouakil D; Fourneret P; Wohl M; Rénéric JP
Encephale; 2005; 31(3):337-48. PubMed ID: 16142049
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
Stuhec M; Munda B; Svab V; Locatelli I
J Affect Disord; 2015 Jun; 178():149-59. PubMed ID: 25813457
[TBL] [Abstract][Full Text] [Related]
17. Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis.
Rodrigues R; Lai MC; Beswick A; Gorman DA; Anagnostou E; Szatmari P; Anderson KK; Ameis SH
J Child Psychol Psychiatry; 2021 Jun; 62(6):680-700. PubMed ID: 32845025
[TBL] [Abstract][Full Text] [Related]
18. Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents.
Gillies D; Sinn JKh; Lad SS; Leach MJ; Ross MJ
Cochrane Database Syst Rev; 2012 Jul; 2012(7):CD007986. PubMed ID: 22786509
[TBL] [Abstract][Full Text] [Related]
19. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
Roskell NS; Setyawan J; Zimovetz EA; Hodgkins P
Curr Med Res Opin; 2014 Aug; 30(8):1673-85. PubMed ID: 24627974
[TBL] [Abstract][Full Text] [Related]
20. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.
King S; Griffin S; Hodges Z; Weatherly H; Asseburg C; Richardson G; Golder S; Taylor E; Drummond M; Riemsma R
Health Technol Assess; 2006 Jul; 10(23):iii-iv, xiii-146. PubMed ID: 16796929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
